+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmaceutical CDMO Market Size, Share & Trends Analysis Report by Product (API, Drug Product), Workflow (Clinical, Commercial), Application (Oncology, Infectious Diseases, Neurological Disorders), Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 342 Pages
  • March 2024
  • Region: Global
  • Grand View Research
  • ID: 5831007
Description Jump to:
The global pharmaceutical CDMO market size is anticipated to reach USD 235.5 billion by 2030 and it is projected to grow at a CAGR of 7.2% from 2024 to 2030. A growing consumption of biopharmaceuticals, rising demand for advanced therapeutics, demand for orphan drug discovery, upsurge number of clinical trials and increasing demand for one-stop-shop CDMOS are anticipated to influence the global market positively.

In addition, increasing pharmaceutical R&D investments can drive the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in R&D activities of pharmaceuticals. For instance, in 2022, F. Hoffmann La Roche increased its R&D spending to USD 14.7 billion from USD 13.3 billion in the previous year. Another major player in pharmaceutical R&D expenditures for the same period was Merck & Co., allocating USD 13.5 billion to R&D. Janssen, the pharmaceutical arm of Johnson & Johnson, followed with an investment of USD 11.6 billion, slightly lower than the previous year's USD 11.9 billion.

Besides, increasing outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the market. The trend of outsourcing activities in pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.

Notably, in the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across product development phases. At the same time, outsourcing serves as a risk-averse alternative. In addition, having a limited understanding of the required scale for current & future product offerings or market penetration poses significant hurdles in designing and scaling manufacturing for in-house production. Consequently, the preference for outsourcing has grown as an effective strategy until market demand for products becomes well-established & understood.

Furthermore, the global distribution of clinical trials is expected to boost market growth. Clinical trials are executed globally, and their geographical distribution is shaped by diverse factors such as disease prevalence, regulatory conditions, population demographics, healthcare infrastructure, and cost considerations. As of February 2024, there is a discernible trend towards a more globalized approach to clinical trials. Over half of all registered studies are conducted outside the U.S. Meanwhile, over 35% of trials are exclusively conducted within the U.S. This emphasizes increasing international collaboration in collective pursuit of medical advancement.

Pharmaceutical CDMO Market Report Highlights

  • Based on product, the active pharmaceutical ingredient (API) segment led the market with the largest revenue share of 81.20% in 2023. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and increasing geriatric population are some of the key factors propelling segment growth
  • Based on the workflow, the commercial segment held the largest market share in 2023 attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective
  • Based on application, the oncology segment dominated the market with the largest revenue share of 21.82% in 2023. The segment is driven by an increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology market
  • Asia Pacific dominated the market with the revenue share of 37.64% in 2023. The presence of various factors, such as improved social insurance schemes & constantly improving economic conditions, which allow patients to pay out-of-pocket pharmaceutical costs is expected to drive market significantly

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Internal database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.3.5. Details of Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. Market Definitions
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
1.10.1. Objective - 1
1.10.2. Objective - 2
1.10.3. Objective - 3
1.10.4. Objective - 4
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology outlook
2.2.2. Treatment outlook
2.2.3. Application outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Pharmaceutical CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing consumption of biopharmaceuticals
3.2.1.2. Increasing demand for one-stop-shop CDMOs
3.2.1.3. Rising Demand for Advanced Therapeutics
3.2.1.4. Increasing outsourcing services by pharmaceutical companies
3.2.1.5. Upsurge in the number of clinical trials
3.2.1.6. Increasing pharmaceutical R&D investments
3.2.1.7. Growing demand for orphan drug discovery
3.2.2. Market Restraint Analysis
3.2.2.1. Compliance issues while outsourcing
3.2.2.2. Changing Scenarios within Developing Countries
3.2.2.3. Regulatory and Legal Compliance
3.2.2.4. Contractual Obligation
3.3. Pharmaceutical CDMO Market: Analysis Tools
3.3.1. PORTER’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.4. Industry Ecosystem Analysis
3.4.1. Supply Chain Analysis
3.4.2. Demand Analysis
3.4.3. Raw Material Analysis
3.4.3.1. GMP Material
3.4.3.1.1. Regulatory Landscape
3.4.3.1.2. Adoption Trend Analysis
3.4.3.1.3. Consumer Behavior Analysis
3.4.3.2. Non-GMP Material
3.4.3.2.1. Regulatory Landscape
3.4.3.2.2. Adoption Trend Analysis
3.4.3.2.3. Consumer Behavior Analysis
3.5. Technology Landscape
3.5.1. Integration of AI in pharmaceutical CDMO market
3.5.1.1. Current Dynamics and Future Trends
3.5.1.1.1. Drug Discovery and Design
3.5.1.1.2. AI-Assisted Drug Active Pharmaceutical Ingredient (API) Synthesis
3.5.1.1.3. Process Optimization
3.5.1.1.4. Supply Chain Management
3.5.1.1.5. Clinical Trial Optimization
3.5.1.1.6. Regulatory Compliance
3.6. Total Number of Clinical Trials by Phase & Region (2021 - 2023)
3.6.1. Total Number of Clinical Trials by Phase (2021 - 2023)
3.6.2. Total Number of Clinical Trials by Region (2021 - 2023)
3.6.2.1. Percentage of Clinical Trials by Major Countries in North America:
3.6.2.2. Percentage of Clinical Trials by Major Countries in Europe:
3.6.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
3.6.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
3.6.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
3.6.3. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
3.7. COVID-19 Impact Analysis
3.7.1. Covid-19 Impact on Pharmaceutical CDMO Market
3.7.2. Covid-19 Impact on Pharmaceutical Outsourcing Market
3.7.2.1. Long-term effects of the COVID-19 pandemic on pharmaceutical outsourcing on the Market
3.7.3. Post Covid-19 Impact and Recovery Analysis
3.7.3.1. Pre-pandemic bioCDMO Capacity Challenges
3.7.3.2. BioCDMO Industry Growth
3.7.3.3. Post-COVID-19 Revenue and Capacity Projections
3.7.3.4. COVID-19 Reformation Strategies
3.7.4. Covid-19 Impact on Key Market Players
Chapter 4. Pharmaceutical CDMO Market: Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. API
4.1.2. Drug Product
4.2. Product Market Share, 2023 & 2030
4.3. Segment Dashboard
4.4. Global Pharmaceutical CDMO Market Movement Analysis
4.5. Global Pharmaceutical CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.5.1. API
4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2. Type
4.5.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.5.1.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.5.1.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.4. Antibody Drug Conjugate (ADC)
4.5.1.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.2.5. Others
4.5.1.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3. Synthesis
4.5.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2. Synthetic
4.5.1.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2.2. Solid
4.5.1.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.2.3. Liquid
4.5.1.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.3.3. Biotech
4.5.1.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4. Drug
4.5.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4.2. Innovative
4.5.1.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.4.3. Generics
4.5.1.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.5. Manufacturing
4.5.1.5.1. Continuous manufacturing
4.5.1.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.1.5.2. Batch manufacturing
4.5.1.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2. Drug Product
4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.2. Oral solid dose
4.5.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.3. Semi-solid dose
4.5.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.4. Liquid dose
4.5.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.5.2.5. Others
4.5.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Pharmaceutical CDMO Market: Workflow Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Clinical
5.1.2. Commercial
5.2. Segment Dashboard
5.3. Global Pharmaceutical CDMO Market Movement Analysis
5.4. Global Pharmaceutical CDMO Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
5.4.1. Clinical
5.4.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.4.2. Commercial
5.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Pharmaceutical CDMO Market: Application Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Oncology
6.1.1.1. Small Molecule
6.1.1.2. Biologics
6.1.2. Infectious Diseases
6.1.3. Neurological Disorders
6.1.4. Cardiovascular Diseases
6.1.5. Metabolic Disorders
6.1.6. Autoimmune Diseases
6.1.7. Respiratory Diseases
6.1.8. Ophthalmology
6.1.9. Gastrointestinal Disorders
6.1.10. Hormonal Disorders
6.1.11. Hematological Disorders
6.1.12. Others
6.2. Segment Dashboard
6.3. Global Pharmaceutical CDMO Market Movement Analysis
6.4. Global Pharmaceutical CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4.1. Oncology
6.4.1.1. Market estimates and forecast 2018 to 2030 (USD million)
6.4.1.2. Small Molecule
6.4.1.2.1. Market estimates and forecast 2018 to 2030 (USD million)
6.4.1.3. Biologics
6.4.1.3.1. Market estimates and forecast 2018 to 2030 (USD million)
6.4.2. Infectious Diseases
6.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.3. Neurological Disorders
6.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.4. Cardiovascular Diseases
6.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.5. Metabolic Disorders
6.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.6. Autoimmune Diseases
6.4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.7. Respiratory Diseases
6.4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.8. Ophthalmology
6.4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.9. Gastrointestinal Disorders
6.4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.10. Hormonal Disorders
6.4.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.11. Hematological Disorders
6.4.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.4.12. Others
6.4.12.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Pharmaceutical CDMO Market: Regional Estimates & Trend Analysis by Product, Workflow, & Application
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
7.4. North America
7.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Scenario
7.4.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Scenario
7.4.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Scenario
7.5.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Scenario
7.5.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Scenario
7.5.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Competitive Scenario
7.5.5.3. Regulatory Scenario
7.5.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Competitive Scenario
7.5.6.3. Regulatory Scenario
7.5.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Competitive Scenario
7.5.7.3. Regulatory Scenario
7.5.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Competitive Scenario
7.5.8.3. Regulatory Scenario
7.5.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Competitive Scenario
7.5.9.3. Regulatory Scenario
7.5.9.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.2. China
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Scenario
7.6.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.3. India
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Scenario
7.6.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.4. Japan
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Scenario
7.6.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Scenario
7.6.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Competitive Scenario
7.6.6.3. Regulatory Scenario
7.6.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Competitive Scenario
7.6.7.3. Regulatory Scenario
7.6.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Competitive Scenario
7.7.2.3. Regulatory Scenario
7.7.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.3. Mexico
7.7.3.1. Key Country Dynamics
7.7.3.2. Competitive Scenario
7.7.3.3. Regulatory Scenario
7.7.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.4. Argentina
7.7.4.1. Key Country Dynamics
7.7.4.2. Competitive Scenario
7.7.4.3. Regulatory Scenario
7.7.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Competitive Scenario
7.8.2.3. Regulatory Scenario
7.8.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Competitive Scenario
7.8.3.3. Regulatory Scenario
7.8.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Competitive Scenario
7.8.4.3. Regulatory Scenario
7.8.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Competitive Scenario
7.8.5.3. Regulatory Scenario
7.8.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Pharmaceutical CDMO Market Share Analysis, 2023
8.3. Major Deals and Strategic Alliances Analysis
8.3.1. Strategy Mapping
8.3.2. Expansion
8.3.3. Partnerships
8.3.4. Acquisitions
8.4. Vendor Landscape
8.4.1. Key company market share analysis, 2023
8.4.2. Lonza
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Thermo Fisher Scientific, Inc.
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Recipharm AB
8.4.4.1. Company Overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Laboratory Corporation of America Holdings (LabCorp)
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Catalent, Inc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. WuXi AppTec, Inc.
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Samsung Biologics
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Piramal Pharma Solutions
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Siegfried Holding AG
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. CordenPharma International
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Cambrex Corporation
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product benchmarking
8.4.12.4. Strategic initiatives
8.4.13. Bushu Pharmaceuticals Ltd.
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product benchmarking
8.4.13.4. Strategic initiatives
8.4.14. Nipro Corporation
8.4.14.1. Company overview
8.4.14.2. Financial performance
8.4.14.3. Product benchmarking
8.4.14.4. Strategic initiatives
8.4.15. Sequens
8.4.15.1. Company overview
8.4.15.2. Financial performance
8.4.15.3. Product benchmarking
8.4.15.4. Strategic initiatives
8.4.16. EuroAPI
8.4.16.1. Company overview
8.4.16.2. Financial performance
8.4.16.3. Product benchmarking
8.4.16.4. Strategic initiatives
8.4.17. Hovione
8.4.17.1. Company overview
8.4.17.2. Financial performance
8.4.17.3. Product benchmarking
8.4.17.4. Strategic initiatives
8.4.18. Axplora
8.4.18.1. Company overview
8.4.18.2. Financial performance
8.4.18.3. Product benchmarking
8.4.18.4. Strategic initiatives
8.4.19. Curia
8.4.19.1. Company overview
8.4.19.2. Financial performance
8.4.19.3. Product benchmarking
8.4.19.4. Strategic initiatives
8.4.20. Dottikon
8.4.20.1. Company overview
8.4.20.2. Financial performance
8.4.20.3. Product benchmarking
8.4.20.4. Strategic initiatives
8.4.21. Almac
8.4.21.1. Company overview
8.4.21.2. Financial performance
8.4.21.3. Product benchmarking
8.4.21.4. Strategic initiatives
8.4.22. FIS - Fabbrica Italiana Sintetici S.p.A.
8.4.22.1. Company overview
8.4.22.2. Financial performance
8.4.22.3. Product benchmarking
8.4.22.4. Strategic initiatives
8.4.23. Evonik
8.4.23.1. Company overview
8.4.23.2. Financial performance
8.4.23.3. Product benchmarking
8.4.23.4. Strategic initiatives
8.4.24. Carbogen Amcis
8.4.24.1. Company overview
8.4.24.2. Financial performance
8.4.24.3. Product benchmarking
8.4.24.4. Strategic initiatives
8.4.25. Farmhispania
8.4.25.1. Company overview
8.4.25.2. Financial performance
8.4.25.3. Product benchmarking
8.4.25.4. Strategic initiatives
8.4.26. Uquifa
8.4.26.1. Company overview
8.4.26.2. Financial performance
8.4.26.3. Product benchmarking
8.4.26.4. Strategic initiatives
8.4.27. Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
8.4.27.1. Company Overview
8.4.27.2. Financial performance
8.4.27.3. Product benchmarking
8.4.27.4. Strategic initiatives
8.4.28. Pfizer Centre One
8.4.28.1. Company overview
8.4.28.2. Financial performance
8.4.28.3. Product benchmarking
8.4.28.4. Strategic initiatives
8.4.29. Fareva
8.4.29.1. Company Overview
8.4.29.2. Financial performance
8.4.29.3. Product benchmarking
8.4.29.4. Strategic initiatives
8.4.30. Sterling
8.4.30.1. Company overview
8.4.30.2. Financial performance
8.4.30.3. Product benchmarking
8.4.30.4. Strategic initiatives
8.4.31. Veranova
8.4.31.1. Company overview
8.4.31.2. Financial performance
8.4.31.3. Product benchmarking
8.4.31.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America Pharmaceutical CDMO market, by region, 2018 - 2030 (USD Million)
Table 3 North America Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 4 North America Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 5 North America Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 6 U.S. Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 7 U.S. Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 8 U.S. Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 9 Canada Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 10 Canada Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 11 Canada Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 12 Europe Pharmaceutical CDMO market, by region, 2018 - 2030 (USD Million)
Table 13 Europe Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 14 Europe Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 15 Europe Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 16 UK Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 17 UK Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 18 UK Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 19 Germany Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 20 Germany Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 21 Germany Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 22 France Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 23 France Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 24 France Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 25 Italy Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 26 Italy Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 27 Italy Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 28 Spain Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 29 Spain Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 30 Spain Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 31 Denmark Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 32 Denmark Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 33 Denmark Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 34 Sweden Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 35 Sweden Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 36 Sweden Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 37 Norway Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 38 Norway Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 39 Norway Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 40 Asia Pacific Pharmaceutical CDMO market, by region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 43 Asia Pacific Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 44 Japan Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 45 Japan Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 46 Japan Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 47 China Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 48 China Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 49 China Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 50 India Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 51 India Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 52 India Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 53 Australia Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 54 Australia Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 55 Australia Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 56 South Korea Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 57 South Korea Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 58 South Korea Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 59 Thailand Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 60 Thailand Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 61 Thailand Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 62 Latin America Pharmaceutical CDMO market, by region, 2018 - 2030 (USD Million)
Table 63 Latin America Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 64 Latin America Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 65 Latin America Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 66 Brazil Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 67 Brazil Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 68 Brazil Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 69 Mexico Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 70 Mexico Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 71 Mexico Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 72 Argentina Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 73 Argentina Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 74 Argentina Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 75 MEA Pharmaceutical CDMO market, by region, 2018 - 2030 (USD Million)
Table 76 MEA Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 77 MEA Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 78 MEA Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 79 South Africa Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 80 South Africa Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 81 South Africa Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 85 UAE Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 86 UAE Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 87 UAE Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
Table 88 Kuwait Pharmaceutical CDMO market, by product, 2018 - 2030 (USD Million)
Table 89 Kuwait Pharmaceutical CDMO market, by workflow, 2018 - 2030 (USD Million)
Table 90 Kuwait Pharmaceutical CDMO market, by application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Pharmaceutical CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Parent market outlook, 2022 (USD Billion)
Fig. 16 Ancillary market outlook, 2022 (USD Billion)
Fig. 17 Pharmaceutical CDMO market dynamics
Fig. 18 US FDA biologics approval
Fig. 19 Porter’s five forces analysis
Fig. 20 Pharmaceutical CDMO market: PESTEL analysis
Fig. 21 Percentage of clinical trials by major countries in North America
Fig. 22 Percentage of clinical trials by major countries in Europe
Fig. 23 Percentage of clinical trials by major countries in Asia Pacific
Fig. 24 Percentage of clinical trials by major countries in Latin America
Fig. 25 Percentage of clinical trials by major countries in Middle East & Africa
Fig. 26 Average cost by phase
Fig. 27 Clinical trial cost per indication (USD Millions)
Fig. 28 Average Cost of Clinical Trials by Major Countries
Fig. 29 Pharmaceutical CDMO market: Product outlook and key takeaways
Fig. 30 Pharmaceutical CDMO market: Product movement analysis
Fig. 31 API pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 API type pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Traditional active pharmaceutical ingredient (traditional API) CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Highly potent active pharmaceutical ingredient (HP-API) CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Biologics pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Monoclonal antibodies pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Antibody drug conjugate (ADC) pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Others pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Synthesis pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Synthetic pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Solid synthetic pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Liquid synthetic pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD million)
Fig. 43 Biotech pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Drug pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Innovative pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Generics pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Manufacturing CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Continuous manufacturing pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Batch manufacturing pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Drug product pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Oral solid dose pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Semisolid dose pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Liquid dose pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Others pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Pharmaceutical CDMO market: Workflow outlook and key takeaways
Fig. 56 Pharmaceutical CDMO market: Workflow movement analysis
Fig. 57 Clinical pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Commercial pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Pharmaceutical CDMO market: Application outlook and key takeaways
Fig. 60 Pharmaceutical CDMO market: Application movement analysis
Fig. 61 Oncology pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Small molecules oncology pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Biologics oncology pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Infectious diseases pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 65 Neurological disorders pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 Cardiovascular disease pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 67 Metabolic disorders pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Autoimmune diseases pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 69 Respiratory diseases pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Ophthalmology pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 71 Gastrointestinal disorders pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Hormonal disorders pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 73 Hematological disorders pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Others pharmaceutical CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Regional market: Key takeaways
Fig. 76 Regional outlook, 2023 & 2030
Fig. 77 Regional outlook, 2023 & 2030
Fig. 78 North America pharmaceutical CDMO market, 2018 - 2030 (USD Million)
Fig. 79 Key country dynamics
Fig. 80 US pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Key country dynamics
Fig. 82 Canada pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Europe pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 UK pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Key country dynamics
Fig. 87 Germany pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 France pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Key country dynamics
Fig. 91 Italy pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 Spain pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Denmark pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 96 Key country dynamics
Fig. 97 Sweden pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Key country dynamics
Fig. 99 Norway pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 100 Asia Pacific pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 101 Key country dynamics
Fig. 102 China pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Key country dynamics
Fig. 104 Regulatory bodies in India involved in pharmaceutical regulations
Fig. 105 India pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 Key country dynamics
Fig. 107 Clinical Trial Authorization Process in Japan
Fig. 108 Clinical research of medical products in Japan
Fig. 109 Japan pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 110 Key country dynamics
Fig. 111 Australia pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 112 Key country dynamics
Fig. 113 Clinical Trial Approval Process in South Korea
Fig. 114 South Korea pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 115 Key country dynamics
Fig. 116 Thailand pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 117 Latin America pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 118 Key country dynamics
Fig. 119 Brazil pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 120 Key country dynamics
Fig. 121 Mexico pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 122 Key country dynamics
Fig. 123 Argentina pharmaceuticals registration details
Fig. 124 Argentina pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 125 MEA pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 126 Key country dynamics
Fig. 127 South Africa pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 128 Key country dynamics
Fig. 129 Saudi Arabia pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 130 Key country dynamics
Fig. 131 Clinical Trial Authorization Process UAE
Fig. 132 UAE pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 133 Key country dynamics
Fig. 134 Regulatory framework: South Africa
Fig. 135 Kuwait pharmaceutical CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 136 Key company categorization
Fig. 137 Product/service heat map analysis
Fig. 138 Strategic Framework

Companies Mentioned

  • Lonza
  • Thermo Fisher Scientific, Inc.
  • Recipharm AB
  • Laboratory Corporation of America Holdings (LabCorp)
  • Catalent, Inc.
  • WuXi AppTec, Inc.
  • Samsung Biologics
  • Piramal Pharma Solutions
  • Siegfried Holding AG
  • CordenPharma International
  • Cambrex Corporation
  • Bushu Pharmaceuticals Ltd.
  • Nipro Corporation
  • Sequens
  • EuroAPI
  • Hovione
  • Axplora
  • Curia
  • Dottikon
  • Almac
  • FIS - Fabbrica Italiana Sintetici S.p.A.
  • Evonik
  • Carbogen Amcis
  • Farmhispania
  • Uquifa
  • Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
  • Pfizer Centre One
  • Fareva
  • Sterling
  • Veranova

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages342
PublishedMarch 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 146 Billion
Forecasted Market Value ( USD ) by 2030 $ 235.5 Billion
Compound Annual Growth Rate7.2%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 241 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Active Pharmaceutical Ingredients CDMO Market by Drug, Product, Synthesis, Workflow, Application - Global Forecast 2025-2030 - Product Image

Active Pharmaceutical Ingredients CDMO Market by Drug, Product, Synthesis, Workflow, Application - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Pharmaceutical Contract Development And Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 317 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.